34. EVALUATION OF THE SAFETY OF STEMSUP AEROSOL THERAPY IN PATIENTS WITH CHRONIC OBSTRUCTION PULMONARY DISEASE
Main Article Content
Abstract
Objective: To describe the clinical and paraclinical characteristics and initially evaluate the safety of Stemsup aerosol therapy in patients with chronic obstructive pulmonary disease.
Materials and Methods: This is an interventional, open-label, single-group study on 30 patients with COPD groups C and D treated at the Tuberculosis and Lung Disease Department of Military Hospital 175 from 8/2021 - 12/2023.
Results: 100% of patients were male, with an average age of 67.5 ± 6.9 years old. The average mMRC score was 2.23 ± 0.57. 6MWT is 326.7 ± 88.2 m. The average CAT score was 18.1 ± 4.9 points. The average BODE score is 4.33 ± 1.62, of which BODE III accounts for the highest percentage (40%),and the lowest is BODE IV accounting for 10%. The average values of lung ventilation indicators in the studied patients all decreased compared to LLN, in which FEV1(%LLN) decreased significantly (45.1 ± 14.9%LLN). Side effects only occurred in 1 case of increased difficulty breathing, accounting for 3.3%. 13.3% of patients had a mild and transient increase in CRP after 1 month of Stemsup aerosol therapy. There were no cases of serious complications after using Stemsup.
Conclusion: Stemsup aerosol therapy in COPD patients was well tolerated without significant serious side effects. This is a promising method for the treatment of COPD patients.
Article Details
Keywords
Chronic obstruction pulmonary disease, stemsup, safety.
References
obstructive pulmonary disease: current burden
and future projections. The European respiratory
journal 2006, 27(2):397-412.
[2] Mathers CD, Loncar D, Projections of global
mortality and burden of disease from 2002 to
2030. PLoS medicine 2006, 3(11):e442.
[3] Miniño AM, Murphy SL, Xu J et al., Deaths:
final data for 2008, United States. National vital
statistics reports: from the Centers for Disease
Control and Prevention, National Center for
Health Statistics, National Vital Statistics System
2011, 59(10):1-126.
[4] Wu M, Han Z-B, Liu JF et al., Serum-free
media and the immunoregulatory properties of
mesenchymal stem cells in vivo and in vitro.
Cellular Physiology and Biochemistry 2014,
33(3):569-580.
[5] Tamama K, Kerpedjieva SS, Acceleration of
Wound Healing by Multiple Growth Factors and
Cytokines Secreted from Multipotential Stromal
Cells/Mesenchymal Stem Cells. Advances in
wound care 2012, 1(4):177-182.
[6] Gupta N, Malhotra N, Ish P, GOLD 2021
guidelines for COPD—what’s new and why.
Advances in respiratory medicine 2021,
89(3):344-346.
[7] Lê Thị Bích Phượng, Nghiên cứu hiệu quả của tế
bào gốc trung mô dây rốn trẻ sơ sinh trong điều
trị bệnh phổi tắc nghẽn mạn tính; Luận án tiến sĩ,
Học viện quân y; 2023.
[8] Weiss DJ, Casaburi R, Flannery R et al.,
A placebo-controlled, randomized trial of
mesenchymal stem cells in COPD; Chest 2013,
143(6):1590-1598.
[9] Ribeiro-Paes JT, Bilaqui A, Greco OT et al.,
Unicentric study of cell therapy in chronic
obstructive pulmonary disease/pulmonary
emphysema; International journal of chronic
obstructive pulmonary disease 2011:63-71.